Osteopore (ASX: OSX) continues penetrating global markets with breakthrough bone regeneration products (w/ Carl Runde)

Small Caps - A podcast by Small Caps

Try Bookbeat 60! days for free, click here

Try Bookbeat 60! days for free, click here

Enjoy a whole world of audiobooks and e-books, everything from new releases to the classics

 Sponsored

Categories:

Business

Osteopore (ASX: OSX) chief financial officer Carl Runde joins Small Caps to discuss the company's breakthrough bioresorbable products which facilitate bone regeneration. The current target markets for Osteopore's products are worth more than US$103 billion. Compared to current procedures, Osteopore's bone regeneration products offer improved patient outcomes while also reducing overall healthcare costs.